CIRM Board Chairman Vito Imbasciani, with interim president Jonathan Thomas, photo courtesy of CIRMThe former chairman of the California stem cell agency is back on the job with the $12 billion agency – this time as its interim president while a search proceeds for a permanent chief executive officer.
The Sue and Bill Gross Stem Cell Research building at University of California Irvine, a CIRM major facility. Photo courtesy of CIRMCalifornia’s $12 billion stem cell and gene therapy program could be treading water for the next 12 months in the view of at least one of its leaders as it searches for a new president of the 19-year-old enterprise. Past presidential searches have been burdened by a legal, dual executive arrangement that has been described by a former board member as a “dog’s breakfast.”
Gene therapy, image by CI PhotosThe neuro task force of the California Institute of Regenerative Medicine, chaired by CIRM Director Larry Goldstein, is scheduled to meet next Wednesday morning (October 18th) to discuss an overall funding approach for allocating $1.5 billion in research toward neuro diseases like brain cancer and epilepsy.
Image by GoodIdeas via ShutterstockDirectors of the $12 billion California stem cell agency will face a fundamental question next week that could determine whether its efforts to produce revolutionary treatments for afflictions ranging from heart disease to cancer will live or die.
Image by Giovanni Cancemi via ShutterstockIt was a $24-million-a-minute meeting for California’s stem cell and gene therapy agency.
Photo by ANDREI ASKIRKA via ShutterstockNine California research organizations will vie behind closed doors this week as the state’s stem cell agency scores their bids to kick off what would be a first-in-the-nation, $80 million manufacturing network to speed the development of revolutionary medical therapies.
Come March 28, Vito Imbascani is scheduled to be sworn in as the new chairman of the $12 billion California stem cell agency – an 18-year-old state program to develop revolutionary treatments for such things as brain and blood cancers, heart disease, diabetes, sickle cell disease, spina bifida, incontinence, blindness, arthritis, HIV, stroke, epilepsy and much more.
Gov. Gavin Newsom at the State of the State Address in January. (Photo: Sheila Fitzgerald)Gov. Gavin Newsom has rebuked California’s stem cell agency about its conduct of the election of a new chairperson for the $12 billion enterprise, a process that has been disrupted with the withdrawal of one candidate and the addition of a new one.
Andrea Fernandez and her son Jakob, who suffers from 'bubble boy' disease. (Photo: Courtesy of Fernandez family)Nearly three years after a British firm abandoned a successful therapy for the life-threatening “bubble baby” disease, children will again be treated in a clinical trial backed with millions of dollars from the state of California. “It’s the best Christmas gift ever,” said the mother of an afflicted child, Andrea Fernandez.
A photo illustration of bacteria as seen through a research microscope. (Photo: Per Bengtsson, via Shutterstock)California has another election coming up this fall, but it is not your usual political campaign free-for-all. Instead, it involves the leadership of the $12 billion state stem cell agency, which is trying mightily to develop “miraculous” treatments and cures for diseases that afflict — according to its backers — half of the families in California.